Findings of Research Misconduct, 56042-56043 [2017-25549]

Download as PDF 56042 Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Amy McNulty, Acting Director, Division of the Executive Secretariat. [FR Doc. 2017–25507 Filed 11–24–17; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Chronic Fatigue Syndrome Advisory Committee Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services (HHS) is hereby giving notice that a meeting of the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will take place and will be open to the public. DATES: The CFSAC in person meeting will be held on Wednesday, December 13, 2017, from 9:00 a.m. until 3:30 p.m. and Thursday, December 14, 2017, from 9:00 a.m. until 5:00 p.m. (EST). ADDRESSES: U.S. Department of Health and Human Services, Hubert H. Humphrey Building, Room 800, 200 Independence Avenue SW., Washington, DC 20201. FOR FURTHER INFORMATION CONTACT: Commander Gustavo Ceinos, MPH, Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee, Department of Health and Human Services, 200 Independence Avenue SW., Room 728F6, Washington, DC 20201. Please direct all inquiries to cfsac@hhs.gov or 202–690–7650. SUPPLEMENTARY INFORMATION: The CFSAC is authorized under 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended. The purpose of the CFSAC is to provide advice and recommendations to the Secretary of Health and Human Services, through the Assistant Secretary for Health (ASH), on issues related to myalgic encephalomyelitis/chronic fatigue asabaliauskas on DSKBBXCHB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:59 Nov 24, 2017 Jkt 244001 syndrome (ME/CFS). The issues can include factors affecting access and care for persons with ME/CFS; the science and definition of ME/CFS; and broader public health, clinical, research, and educational issues related to ME/CFS. The agenda for this meeting, call-in information and location will be posted on the CFSAC Web site http:// www.hhs.gov/ash/advisory-committees/ cfsac/meetings/index.html. Request to speak to the committee: Each day of the meeting an hour has been scheduled for public comments via telephone or in person. Individuals will have three minutes to present their comments. Priority will be given to individuals who have not provided public comment within the previous twelve months. We are unable to place international calls for public comments. To request a time slot for public comments, please send an email to cfsac@hhs.gov by close of business on Monday, November 27, 2017. The email should contain the speaker’s name and the phone number that will be used for public comments. An email from the CFSAC Support Team will be sent back to you confirming receipt of your request. If the email confirmation is not received within two working days, please call 202–690–7650. Request to provide written comments: Individuals who would like to provide only written testimony to the Committee members and do not wish to speak, should indicate so in their email when submitting their written testimony. It is preferred, but not required, that the submitted testimony be prepared in digital format and typed using a 12pitch font. Written comments must not exceed 5 single-space pages, and it is preferred, but not required that the document be prepared in the MS Word format. Please note that PDF files, handwritten notes, charts, and photographs cannot be accepted. Materials submitted should not include sensitive personal information, such as social security number, birthdates, driver’s license number, passport number, financial account number, or credit or debit card number. If you wish to remain anonymous please specify this in your email, otherwise your name will be included at the top of your written comments. The Committee welcomes input on any topic related to ME/CFS. PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 Dated: November 17, 2017. Gustavo Ceinos, CDR, USPHS, Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee. [FR Doc. 2017–25550 Filed 11–24–17; 8:45 am] BILLING CODE 4150–42–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Mahandranauth Chetram, Ph.D., Georgetown University and Emory School of Medicine: Based on the report of an investigation conducted by Georgetown University (GU), Respondent’s admission at Emory School of Medicine (ESOM), and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Mahandranauth Chetram, former postdoctoral fellow, Department of Oncology, GU, and former postdoctoral fellow, Department of Pediatrics, ESOM, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R01 CA113447, R01 CA092306, and T32 CA09686 while at GU, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grant R01 DK059380 while at ESOM. ORI found that Respondent engaged in research misconduct at GU by falsifying Western blot images and polymerase chain reaction (PCR) data included in an unfunded grant application, R01 CA193344–01A1, and in a manuscript submitted to Cancer Cell (‘‘The DNA Repair Protein, NTHL1 Functions as an Oncoprotein by Activating the Canoncial Wnt Pathway.’’ Submitted to Cancer Cell; hereafter referred to as the ‘‘Cancer Cell manuscript’’). Subsequently, after Respondent was aware of the research misconduct findings from GU, Respondent engaged in research misconduct at ESOM and falsified RT– PCR data on Excel spreadsheets in the research record and in a figure generated from the false data included in a manuscript submitted to and withdrawn from Scientific Reports (‘‘Immipramine Blue Sensitively and Selectively Targets FLT3–ITD Positive Acute Myeloid Leukemia Cells.’’ Scientific Reports 7(1):4447, 2017 June E:\FR\FM\27NON1.SGM 27NON1 Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices 30; doi:10.1038/s41598–017–04796–1. PMID: 28667329. Submitted to Scientific Reports [withdrawn]; hereafter referred to as the ‘‘Scientific Reports manuscript’’). Specifically, ORI found: • While at GU, Respondent falsified Western blot images and qPCR experiments examining mechanisms underlying the hypothesis that the DNA repair protein, NTHL–1, regulates wingless signaling in cancer cells. False Western blot images were included in Figures 6A and S7L in the Cancer Cell manuscript, and the same Figure 6A was included as Figure 8A in grant application R01 CA193344–01A1. False qPCR data were included in Figures 3F and 5D in the Cancer Cell manuscript and Figures 5C (MCF7 panel) and 5E of grant application R01 CA193344–01A1. • While at ESOM, Respondent falsified data on Excel spreadsheets for eight (8) RT–PCR experiments measuring the expression of various genes in leukemia cell lines and included false data in the Scientific Reports manuscript. Dr. Chetram entered into a Voluntary Exclusion Agreement and voluntarily agreed for a period of three (3) years, beginning on October 19, 2017: (1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376 et seq.) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); and (2) To exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: asabaliauskas on DSKBBXCHB2PROD with NOTICES Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. Kathryn M. Partin, Director, Office of Research Integrity. [FR Doc. 2017–25549 Filed 11–24–17; 8:45 am] BILLING CODE 4150–31–P VerDate Sep<11>2014 16:59 Nov 24, 2017 Jkt 244001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Eye Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Eye Council. Date: January 18, 2018. Open: 8:30 a.m. to 1:00 p.m. Agenda: Following opening remarks by the Director, NEI, there will be presentations by the staff of the institute and discussions concerning Institute programs. Place: Fishers Lane Conference Center, Terrace Level, 5635 Fishers Lane, Rockville, MD 20852. Closed: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Fishers Lane Conference Center, Terrace Level, 5635 Fishers Lane, Rockville, MD 20852. Contact Person: Paul A. Sheehy, Ph.D., Executive Secretary, Division of Extramural Affairs, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 12300, Bethesda, MD 20892, 301–451–2020, ps32h@nih.gov. Information is also available on the Institute’s/Center’s home page:www.nei.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 56043 Dated: November 20, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–25449 Filed 11–24–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, SBIR E-Learning Review. Date: December 4, 2017. Time: 11:00 a.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: NIEHS/National Institutes of Health, Keystone Building, 530 Davis Drive, Room 3118, Research Triangle Park, NC 27709 (Teleconference). Contact Person: Janice B Allen, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Science, P. O. Box 12233, MD EC–30/ Room 3170, B Research Triangle Park, NC 27709, 919/541–7556, allen9@niehs.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel Assay Development: Toxicity Testing with Differentiated Cells Special Emphasis Panel Review. Date: December 5, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: NIEHS/National Institutes of Health, Keystone Building, 530 Davis Drive, Research Triangle Park, NC 27713 (Virtual Meeting). Contact Person: Leroy Worth, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P. O. Box 12233, MD EC– E:\FR\FM\27NON1.SGM 27NON1

Agencies

[Federal Register Volume 82, Number 226 (Monday, November 27, 2017)]
[Notices]
[Pages 56042-56043]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25549]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    Notice is hereby given that the Office of Research Integrity (ORI) 
has taken final action in the following case:
    Mahandranauth Chetram, Ph.D., Georgetown University and Emory 
School of Medicine: Based on the report of an investigation conducted 
by Georgetown University (GU), Respondent's admission at Emory School 
of Medicine (ESOM), and additional analysis conducted by ORI in its 
oversight review, ORI found that Dr. Mahandranauth Chetram, former 
postdoctoral fellow, Department of Oncology, GU, and former 
postdoctoral fellow, Department of Pediatrics, ESOM, engaged in 
research misconduct in research supported by National Cancer Institute 
(NCI), National Institutes of Health (NIH), grants R01 CA113447, R01 
CA092306, and T32 CA09686 while at GU, and National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grant R01 
DK059380 while at ESOM.
    ORI found that Respondent engaged in research misconduct at GU by 
falsifying Western blot images and polymerase chain reaction (PCR) data 
included in an unfunded grant application, R01 CA193344-01A1, and in a 
manuscript submitted to Cancer Cell (``The DNA Repair Protein, NTHL1 
Functions as an Oncoprotein by Activating the Canoncial Wnt Pathway.'' 
Submitted to Cancer Cell; hereafter referred to as the ``Cancer Cell 
manuscript''). Subsequently, after Respondent was aware of the research 
misconduct findings from GU, Respondent engaged in research misconduct 
at ESOM and falsified RT-PCR data on Excel spreadsheets in the research 
record and in a figure generated from the false data included in a 
manuscript submitted to and withdrawn from Scientific Reports 
(``Immipramine Blue Sensitively and Selectively Targets FLT3-ITD 
Positive Acute Myeloid Leukemia Cells.'' Scientific Reports 7(1):4447, 
2017 June

[[Page 56043]]

30; doi:10.1038/s41598-017-04796-1. PMID: 28667329. Submitted to 
Scientific Reports [withdrawn]; hereafter referred to as the 
``Scientific Reports manuscript'').
    Specifically, ORI found:
     While at GU, Respondent falsified Western blot images and 
qPCR experiments examining mechanisms underlying the hypothesis that 
the DNA repair protein, NTHL-1, regulates wingless signaling in cancer 
cells. False Western blot images were included in Figures 6A and S7L in 
the Cancer Cell manuscript, and the same Figure 6A was included as 
Figure 8A in grant application R01 CA193344-01A1. False qPCR data were 
included in Figures 3F and 5D in the Cancer Cell manuscript and Figures 
5C (MCF7 panel) and 5E of grant application R01 CA193344-01A1.
     While at ESOM, Respondent falsified data on Excel 
spreadsheets for eight (8) RT-PCR experiments measuring the expression 
of various genes in leukemia cell lines and included false data in the 
Scientific Reports manuscript.
    Dr. Chetram entered into a Voluntary Exclusion Agreement and 
voluntarily agreed for a period of three (3) years, beginning on 
October 19, 2017:
    (1) To exclude himself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility for or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq.) of OMB Guidelines to Agencies on 
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively 
the ``Debarment Regulations''); and
    (2) To exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017-25549 Filed 11-24-17; 8:45 am]
BILLING CODE 4150-31-P